科研成果详情

题名A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations
作者
发表日期2023-06-15
发表期刊Cancer communications (London, England)   影响因子和分区
语种英语
原始文献类型Letter
ISSN2523-3548
卷号43期号:9
DOI10.1002/cac2.12456
收录类别PUBMED
URL查看原文
PubMed ID37322852
引用统计
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/181173
专题第一临床医学院(信息与工程学院)、附属第一医院_内科学_呼吸与危重症医学科
作者单位
1.Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.;
2.Department of Respiratory Medicine, Xiangya Hospital Central South University, Changsha, Hunan, P. R. China.;
3.Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.;
4.Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai, P. R. China.;
5.Department of Respiratory Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, P. R. China.;
6.Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. China.;
7.Department of Medical Thoracic Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Hangzhou, Zhejiang, P. R. China.;
8.Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, P. R. China.;
9.Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, P. R. China.;
10.Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P. R. China.;
11.Huadong Global Development Center, Hangzhou ZhongMei HuaDong Pharmaceutical Company, Hangzhou, Zhejiang, P. R. China.;
12.Department of Respiratory Medicine, General Hospital of Eastern Theater Command, Nanjing, Jiangsu, P. R. China.;
13.Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang, P. R. China.
推荐引用方式
GB/T 7714
Pingli Wang,Liming Cao,Panwen Tian,et al. A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations[J]. Cancer communications (London, England),2023,43(9).
APA Pingli Wang., Liming Cao., Panwen Tian., Shengxiang Ren., Liyun Miao., ... & Kai Wang. (2023). A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations. Cancer communications (London, England), 43(9).
MLA Pingli Wang,et al."A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations".Cancer communications (London, England) 43.9(2023).

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Pingli Wang]的文章
[Liming Cao]的文章
[Panwen Tian]的文章
百度学术
百度学术中相似的文章
[Pingli Wang]的文章
[Liming Cao]的文章
[Panwen Tian]的文章
必应学术
必应学术中相似的文章
[Pingli Wang]的文章
[Liming Cao]的文章
[Panwen Tian]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。